Chr. Hansen and Partner Biofarma Debut New Probiotic Concept
17 Oct 2013 --- Chr. Hansen and partner Biofarma are debuting a powerful new probiotic concept: A convenient, drinkable probiotic shot in a user-friendly mini-bottle using the unique DRYCAP technology. The first off-the-shelf shot is a healthy and tasty solution combining BB-12 and fiber. The new probiotic shot concept is launched at the CPhI 2013 event held in Frankfurt, Germany October 22-24.
Here visitors will have the opportunity to see and taste the probiotic shot containing Chr. Hansen’s flagship probiotic strain BB-12 – the world’s best documented Bifidobacterium – with fiber in the form of fructooligosaccharides (FOS). The product, which can be promoted as a “2 in 1” or “dual action” product, addresses gastrointestinal function and irregularities.
“We are really looking forward to showcasing this healthy, lemon-flavored shot that combines two ingredients which both have a long history of use, high consumer awareness and acceptance,” says Chr. Hansen’s Lasse Nagell, Sales & Marketing Vice President, Health & Nutrition.
The attractive combination probiotic and fiber comes in a 10 ml liquid shot format, a convenient dosage form designed for the health-conscious consumer who prefers to drink shots rather than swallow capsules or tablets. The probiotics are stored in an alu-blister which is integrated into the mini-bottle cap ? the DRYCAP, a patented technology manufactured by Chr. Hansen’s trusted partner Biofarma. DRYCAP allows live probiotics in a dry environment, thereby preserving their documented health benefits. “The consumer simply dispenses the probiotics into the liquid, shakes the bottle to disperse the probiotics, and drinks the shot ? a quick and tasty way to get your probiotics on the go,” Nagell says.
“The BB-12 + fiber shot is the first probiotic liquid shot we propose to the market but there are multiple opportunities to combine ingredients in “dual action” shots. It will be interesting to discuss the opportunities with participants at CPhI 2013,” Nagell concludes.
